MED13 Syndrome

Executive Summary

MED13 Syndrome, also termed intellectual developmental disorder-61 (MRD61) or MED13-associated neurodevelopmental disorder, is an extremely rare autosomal dominant condition caused by heterozygous pathogenic variants in the MED13 gene (OMIM #618009) (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). First comprehensively described by Blok and colleagues in 2018, this syndrome is characterized by universal developmental delay/intellectual disability, severe speech and language disorders, and variable features including autism spectrum disorder, attention deficit hyperactivity disorder, dysmorphic facial features, ophthalmologic abnormalities, and mild cardiac anomalies (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5). As of 2025, approximately 26-30 cases have been documented worldwide (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). The disorder results from disrupted function of MED13, a critical subunit of the CDK8-kinase module within the Mediator complex, which regulates RNA polymerase II-mediated transcription (blok2018denovomutations pages 1-2, harper2018thecomplexstructure pages 1-2).

1. Disease Information

Disease Definition and Overview

MED13 Syndrome is a novel neurodevelopmental disorder first systematically characterized in a 2018 GeneMatcher collaboration by Blok et al., who identified 13 affected individuals with protein-altering variants in the MED13 gene (blok2018denovomutations pages 1-2). The syndrome presents as "a neurodevelopmental disorder characterized by developmental delay and/or intellectual disability, including speech delays or disorders" along with a spectrum of additional features (blok2018denovomutations pages 1-2). As stated in the foundational publication, "All patients had intellectual disability and/or developmental delays, including speech delays or disorders" (blok2018denovomutations pages 1-2).

Key Identifiers

• OMIM ID: #618009 (Intellectual Developmental Disorder-61, MRD61)
• MONDO ID: MONDO:0032485 (as specified by user)
• MED13 Gene: OMIM #603808; located at chromosome 17q23.2 (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
• ICD-11: Not yet specifically coded; would fall under neurodevelopmental disorders
• Category: Mendelian disorder, autosomal dominant

Alternative Names and Synonyms

• Intellectual Developmental Disorder-61 (MRD61)
• MED13-associated syndrome
• MED13-related neurodevelopmental disorder
• MED13-associated intellectual disability

Data Source

Information is derived from aggregated disease-level resources including peer-reviewed case series, systematic genetic studies, and functional characterizations, not from individual patient electronic health records. Primary sources include the foundational 2018 Blok et al. cohort study (blok2018denovomutations pages 1-2), subsequent case reports from 2021-2025 (tolmacheva2024expandingphenotypeof pages 1-2, rivera2024med13genemutation pages 1-2, yang2025anovelframeshift pages 1-2, nardi2021couldthemed13 pages 1-2, yang2025anovelframeshift pages 2-3), and comprehensive reviews of Mediator complex disorders (fazio2025geneticclinicaland pages 1-2, fazio2025geneticclinicaland pages 2-4).

2. Etiology

Disease Causal Factors

Genetic Etiology (Primary Cause):
MED13 Syndrome is caused by heterozygous pathogenic variants in the MED13 gene (NM_005121.3), which encodes the Mediator complex subunit 13 (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3). The MED13 gene consists of 30 exons and encodes a 2,174 amino acid protein (239.3 kDa) that serves as a component of the CDK8-kinase module of the Mediator complex (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3).

The disorder follows an autosomal dominant inheritance pattern with the vast majority of cases arising from de novo variants. In the original cohort of 13 patients, 11 variants were confirmed de novo, and only one was inherited from an affected mother to an affected child, demonstrating vertical transmission with variable expressivity (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5).

Mechanistic Basis:
MED13 is an essential component of the Mediator complex, a large multiprotein assembly (approximately 1.4 MDa in humans) that serves as a critical interface between gene-specific transcription factors and RNA polymerase II (harper2018thecomplexstructure pages 1-2, poss2013themediatorcomplex pages 2-3). As described by Harper and Taatjes (2018), "the Mediator complex is required for expression of most, if not all, pol II transcripts" (harper2018thecomplexstructure pages 1-2). MED13 specifically resides within the CDK8-kinase module, which consists of four proteins: MED13, MED12, CDK8, and cyclin C (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3).

Risk Factors

Genetic Risk Factors:

Causal Variants: The disease is caused by heterozygous loss-of-function or specific gain-of-dysfunction variants in MED13. Variant types include: - Nonsense mutations leading to premature termination (e.g., p.Leu131, p.Arg1400) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Frameshift variants causing truncation (e.g., p.Pro42Leufs6, p.Arg1882Serfs9) (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3) - Missense variants clustering in specific functional domains (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) - In-frame deletions affecting critical residues (e.g., p.Thr326del) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7)

Variant Classification: All pathogenic MED13 variants identified in affected individuals are absent from population databases (gnomAD, TOPMED) and are predicted to be highly deleterious by multiple in silico tools, with CADD scores ranging from 20.5 to 41.0 (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

Modifier Genes: The paralog MED13L may provide partial functional compensation. Studies in knockout mouse embryos demonstrated that "MED13L partially compensates for loss of MED13 function in preimplantation knockout embryos" (miao2018mediatorcomplexcomponent pages 1-2), suggesting genetic background effects involving MED13L expression levels could modify disease severity.

Environmental Risk Factors:
No specific environmental risk factors have been identified for MED13 Syndrome, consistent with its genetic etiology as a de novo dominant Mendelian disorder.

Protective Factors

No genetic or environmental protective factors have been specifically identified for MED13 Syndrome.

Gene-Environment Interactions

Given the Mendelian nature of the disorder with predominantly de novo occurrence, traditional gene-environment interactions have not been characterized. However, epigenetic regulation of MED13 expression during development may influence phenotypic severity.

3. Phenotypes

MED13 Syndrome presents with a consistent core phenotype of neurodevelopmental impairment combined with variable additional features. Below is a comprehensive description of reported phenotypes.

Table: This table summarizes the core and variable clinical features reported for MED13 syndrome, including approximate frequencies, severity patterns, onset, suggested HPO mappings, and supporting citations. It is useful for disease knowledge base curation and phenotype annotation.

Core Phenotypes

Developmental Delay and Intellectual Disability (100% penetrance)

Phenotype Type: Neurodevelopmental impairment; clinical sign and behavioral manifestation

Characteristics: - Severity: Ranges from borderline/mild to moderate intellectual disability (ID); some patients assessed by formal testing showed IQ scores from 35-50 (moderate ID) to 85 (lower range of normal), though most fall in the mild ID range (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Age of Onset: Apparent in infancy; global developmental delay typically recognized within the first year of life - Progression: Generally stable once developmental trajectory is established, though speech may show some improvement with intensive therapy - Frequency: Universal (100%) among all reported cases (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11)

Quality of Life Impact: Significant impact on educational attainment, independence, and adaptive functioning. Most individuals require ongoing educational support and may need assistance with activities of daily living in adulthood.

HPO Terms: HP:0001263 (Global developmental delay); HP:0001249 (Intellectual disability); HP:0001256 (Mild intellectual disability); HP:0002342 (Moderate intellectual disability)

Speech and Language Disorders (100% penetrance)

Phenotype Type: Neurodevelopmental symptom affecting communication

Characteristics: - Severity: Variable from delayed language development to severe speech/language disorder; notably, "speech production was significantly more impaired than language comprehension" in the majority of patients (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Age of Onset: Delays apparent from toddler years onward - Specific Subtypes: Three patients (approximately 23%) presented with childhood apraxia of speech, characterized by "difficulties accurately programming the motor sequences required to produce fluent speech" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5). Patient M had "severe speech/language disorder" with "expressive speech severely affected, with signs of speech apraxia. At the age of 8 years she only used single words and very short sentences" (blok2018denovomutations pages 4-5). Patient K showed "regression at the age of 13 months and has since remained non-verbal" (blok2018denovomutations pages 4-5). - Progression: Speech delays persist, though some improvement with therapy - Frequency: Universal (100%) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5)

Quality of Life Impact: Severe speech impairments profoundly affect social interaction, educational achievement, and frustration levels in affected children.

HPO Terms: HP:0000750 (Delayed speech and language development); HP:0002463 (Language impairment); HP:0012469 (Childhood apraxia of speech); HP:0001344 (Abnormal expressive language)

Common Variable Phenotypes

Autism Spectrum Disorder (38-55%)

Phenotype Type: Behavioral/neurodevelopmental disorder

Characteristics: - Severity: Variable from mild autistic features to formal ASD diagnosis - Age of Onset: Typically recognized in early childhood - Frequency: Five of 13 patients (38%) in the initial cohort; later reviews suggest up to 55% (blok2018denovomutations pages 1-2, rivera2024med13genemutation pages 1-2, nardi2021couldthemed13 pages 1-2)

HPO Terms: HP:0000729 (Autism)

Attention Deficit Hyperactivity Disorder (23%)

Phenotype Type: Behavioral disorder

Frequency: Three of 13 patients (23%) in initial cohort (blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2)

HPO Terms: HP:0007018 (Attention deficit hyperactivity disorder)

Eye and Vision Abnormalities (62%)

Phenotype Type: Structural and functional ophthalmic abnormalities

Characteristics: - Specific Features: Optic nerve abnormalities (pale optic nerves, optic atrophy), Duane anomaly (congenital strabismus with horizontal ophthalmoplegia), astigmatism, nystagmus, retinal abnormalities (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) - Severity: Variable from mild refractive errors to severe optic atrophy with visual impairment - Notable Pattern: Two patients with missense mutations clustering in the C-terminal domain (p.Gln2060Lys and p.Ala2064Val) both presented with Duane anomaly, suggesting potential genotype-phenotype correlation (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) - Age of Onset: Typically congenital or recognized in early childhood - Frequency: Eight of 13 patients (62%) had eye or vision abnormalities (blok2018denovomutations pages 6-7)

HPO Terms: HP:0001098 (Abnormality of the optic nerve); HP:0001138 (Optic atrophy); HP:0009928 (Duane anomaly); HP:0000486 (Strabismus); HP:0000483 (Astigmatism); HP:0000639 (Nystagmus)

Dysmorphic Facial Features

Phenotype Type: Physical manifestation; craniofacial anomaly

Characteristics: - Specific Features: As described by Blok et al., "Overlapping facial characteristics were reported, including widely spaced eyes with narrow palpebral fissures and peri-orbital fullness, a broad and high nasal bridge, full nasal tip, synophrys, a flat philtrum and a wide mouth with thin upper lip" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7) - Severity: Generally mild; may contribute to clinical suspicion but not pathognomonic - Age of Onset: Congenital - Frequency: Common but variable; noted across multiple independent reports (blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5, yang2025anovelframeshift pages 2-3)

Note: One patient initially received a clinical diagnosis of Kabuki syndrome based on facial features before MED13 variant was identified, highlighting phenotypic overlap with other syndromes (nardi2021couldthemed13 pages 1-2).

HPO Terms: HP:0001999 (Abnormality of the face); HP:0000316 (Hypertelorism); HP:0000450 (Broad nasal bridge); HP:0000343 (Long philtrum); HP:0000154 (Wide mouth)

Congenital Heart Defects (15-30%)

Phenotype Type: Structural cardiac anomaly

Characteristics: - Specific Features: Mild defects include dilated aortic root and pulmonary artery, subaortic stenosis (blok2018denovomutations pages 6-7). Severe neonatal case presented with "isthmus hypoplasia, ventricular septal defect, small atrial septal defect, right heart hypertrophy, tricuspid insufficiency, and pulmonary hypertension" (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5) - Severity: Usually mild in typical cases; severe in rare neonatal presentations - Age of Onset: Congenital - Frequency: Two of 13 patients (15%) in initial cohort; higher in expanded case series including severe presentations (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7)

HPO Terms: HP:0001627 (Abnormal heart morphology); HP:0001680 (Coarctation of the aorta); HP:0001629 (Ventricular septal defect); HP:0001631 (Atrial septal defect)

Hypotonia and Motor Delays (23-54%)

Phenotype Type: Neuromuscular symptom; motor developmental delay

Characteristics: - Hypotonia: Reported in three of 13 patients (23%), typically as infantile hypotonia (blok2018denovomutations pages 6-7) - Motor Delays: Seven of 13 patients (54%) showed motor developmental delays, mostly affecting gross motor skills (blok2018denovomutations pages 2-4, blok2018denovomutations pages 6-7) - Age of Onset: Hypotonia apparent in infancy; motor delays recognized in first years - Progression: Hypotonia may improve with age; motor delays persist but some improvement with therapy

HPO Terms: HP:0001252 (Muscular hypotonia); HP:0001270 (Motor delay); HP:0002194 (Delayed gross motor development)

Less Common Phenotypes

Epilepsy and Seizures (8-15%)

Phenotype Type: Neurological disorder; laboratory/clinical abnormality (abnormal EEG)

Characteristics: - Specific Presentations: One patient in original cohort developed "severe drug-resistant myoclonic-atonic epilepsy at 4 years of age with generalized clonic, myoclonic, atonic, tonic and atypical absence seizures" (blok2018denovomutations pages 6-7). More recent reports include epileptic encephalopathy with infantile spasms (rivera2024med13genemutation pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5) - Severity: Can be severe and treatment-resistant when present - Age of Onset: Variable, from infancy to childhood - Frequency: Rare; one of 13 in original cohort; several additional cases in later reports

HPO Terms: HP:0001250 (Seizure); HP:0012469 (Epileptic encephalopathy); HP:0002123 (Generalized myoclonic seizures)

Brain MRI Abnormalities

Phenotype Type: Structural brain abnormality; imaging finding

Characteristics: - Specific Features: Mild frontal atrophy, corpus callosum abnormalities (hypoplasia, agenesis), ventriculomegaly, hydrocephalic changes, optic chiasm atrophy, brainstem atrophy (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, fazio2025geneticclinicaland pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5) - Severity: Variable from mild to severe - Age of Onset: Congenital/developmental - Frequency: Not systematically reported in early cohort; increasingly recognized in recent case reports

HPO Terms: HP:0001273 (Abnormality of the corpus callosum); HP:0002079 (Hypoplasia of the corpus callosum); HP:0002119 (Ventriculomegaly); HP:0007364 (Lissencephaly)

Chronic Constipation and GI Manifestations (31%)

Phenotype Type: Gastrointestinal symptom

Characteristics: - Specific Features: Chronic obstipation reported in four of 13 patients (31%) in original cohort (blok2018denovomutations pages 6-7). Novel complication of congenital megacolon described in Chinese family case (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3) - Severity: Variable; can be severe requiring surgical intervention (megacolon case)

HPO Terms: HP:0002019 (Constipation); HP:0012707 (Megacolon)

Severe Neonatal/Multisystem Presentation (Very Rare)

Phenotype Type: Severe multi-organ involvement

One infant with a de novo p.Pro835Ser variant "presented with congenital heart anomalies, dysmorphic features, hydrocephalic changes, hypoplastic corpus callosum, bilateral optic nerve atrophy, optic chiasm atrophy, brain stem atrophy, and overall a more severe condition compared to previously described patients" and "deceased at 76 days of age due to multiple organ failure" (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5). This case highlights the potential for severe presentations.

4. Genetic/Molecular Information

Table: This table summarizes the reported genetic and molecular features of MED13 syndrome, including representative variants, domains, clustering, functional interpretations, and available in silico evidence. It is useful for disease knowledge base curation and for distinguishing truncating versus hotspot missense mechanisms.

Causal Gene

MED13 (Mediator Complex Subunit 13)

• Gene Symbol: MED13
• OMIM Gene ID: #603808
• Chromosomal Location: 17q23.2 (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3)
• Transcript: NM_005121.3 (reference transcript used in clinical reporting)
• Protein: NP_005112.2; 2,174 amino acids; predicted molecular weight 239.3 kDa (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3)
• HGNC ID: HGNC:2372

Pathogenic Variants

Variant Types and Classification:

The MED13 gene harbors multiple types of pathogenic variants. As summarized by Blok et al. (2018), the cohort included "six affected individuals had mutations that are predicted to truncate the MED13 protein, six had missense mutations, and one had an in-frame-deletion of one amino acid" (blok2018denovomutations pages 1-2).

Truncating Variants (Loss-of-Function): - Nonsense mutations: p.Leu131, p.Leu582, p.Arg1400 (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5) - Frameshift variants: p.Pro42Leufs6, p.Thr1496Metfs11, p.Arg1882Serfs9 (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3) - Mechanism: Truncating variants likely lead to haploinsufficiency. Functional studies on the p.Arg1400* variant demonstrated that "while full-length MED13 protein was present in the patient (and in the controls), no truncated MED13 protein product could be detected" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11), supporting nonsense-mediated decay or rapid degradation of truncated protein. However, "no differences in MED13 transcript levels were detectable between the affected patient and the unaffected parents or controls" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11), suggesting the remaining transcript from the normal allele may partially compensate at the mRNA level, but haploinsufficiency exists at the protein level.

Missense Variants with Clustering:

A striking feature is the clustering of non-truncating variants in two specific protein regions (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11):

1. N-terminal Phosphodegron Hotspot (Thr326/Pro327):
2. Variants: p.Thr326Ile, p.Thr326del, p.Pro327Ser, p.Pro327Gln (blok2018denovomutations pages 1-2, nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 6-7)

3. Functional Consequence: These residues are part of a conserved phosphodegron recognized by the SCF-Fbw7 ubiquitin ligase for MED13 degradation. As Blok et al. explain, "it has already been shown that a specific amino acid substitution at position 326 in MED13 (p.Thr326Ala) leads to impaired binding of Fbw7 to the phosphodegron of MED13/MED13L, thus preventing MED13/MED13L ubiquitination and degradation" (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11). Molecular modeling showed that "all four variants (p.Thr326Ile, p.Thr326del, p.Pro327Ser, p.Pro327Gln) are predicted to alter the phosphorylation and Fbw7 interaction with drastic decreases in binding energy to Fbw7" (blok2018denovomutations pages 7-11). This suggests a dominant-negative or gain-of-dysfunction mechanism wherein the variant protein is stabilized and accumulates, potentially disrupting normal Mediator complex dynamics.

4. C-terminal Hotspot (Gln2060/Ala2064):

5. Variants: p.Gln2060Lys, p.Ala2064Val (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7)
6. Functional Consequence: These C-terminal variants affect conserved surface-exposed motifs. The p.Ala2064Val change is "predicted to be structure-altering through increasing hydrophobic collapse, secondary structure formation, and increasing aliphatic index of a surface exposed linear motif. This results in a decrease of the regions linear interacting peptide potential" (blok2018denovomutations pages 7-11), suggesting altered protein-protein interactions within the Mediator complex or with transcription factors.

Variant Classification (ACMG/AMP): All reported pathogenic variants are classified as pathogenic or likely pathogenic based on: - Absence from population databases (gnomAD, TOPMED) - High conservation of affected residues - High CADD scores (20.5-41.0) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 6-7) - Segregation with disease phenotype - Functional data (for select variants) - Significant enrichment of de novo MED13 variants in DD/ID cohorts (p=0.00371) (blok2018denovomutations pages 7-11)

Allele Frequency: All pathogenic variants identified to date are absent or extremely rare in population databases (gnomAD allele frequency effectively 0 for disease-causing variants) (blok2018denovomutations pages 1-2, blok2018denovomutations pages 7-11), consistent with the severe reproductive fitness impact and predominantly de novo occurrence.

Somatic vs. Germline: All reported variants are germline. One case of suspected paternal germline mosaicism has been reported for a MED13L variant, and a similar mechanism could theoretically occur for MED13, though not yet documented (fazio2025geneticclinicaland pages 1-2).

Functional Consequences: - Loss-of-function variants: Haploinsufficiency mechanism, reducing functional MED13 protein levels - Phosphodegron missense variants: Impaired protein degradation leading to accumulation of dysfunctional MED13, potentially causing dominant-negative effects on Mediator complex function - Other missense variants: Altered protein interactions or structural changes affecting MED13 function within the Mediator complex

Modifier Genes

MED13L:
The paralog MED13L (chromosome 12q24.21) can partially compensate for MED13 loss. Studies show MED13 and MED13L are mutually exclusive within the CDK8-kinase module (miao2018mediatorcomplexcomponent pages 1-2, fazio2025geneticclinicaland pages 2-4). Mouse studies demonstrated that "MED13L partially compensates for loss of MED13 function in preimplantation knockout embryos, but postimplantation development is not rescued by MED13L" (miao2018mediatorcomplexcomponent pages 1-2), suggesting tissue- and stage-specific compensation.

Epigenetic Information

While specific epigenetic changes in MED13 Syndrome patients have not been extensively characterized, the Mediator complex itself regulates epigenetic modifications. The MED13-containing kinase module can phosphorylate chromatin regulators and is involved in coordinating transcriptional responses to epigenetic signals (poss2013themediatorcomplex pages 2-3).

Chromosomal Abnormalities

No large-scale chromosomal abnormalities (aneuploidy, translocations, inversions) involving MED13 have been reported as causes of the syndrome. The disorder results from intragenic sequence variants.

5. Environmental Information

Environmental Factors

No specific environmental factors (toxins, radiation, pollution, occupational exposures) have been identified as contributing to MED13 Syndrome, consistent with its genetic etiology as a predominantly de novo Mendelian disorder.

Lifestyle Factors

Not applicable to disease causation.

Infectious Agents

Not applicable.

6. Mechanism / Pathophysiology

Overview of Molecular Mechanisms

MED13 Syndrome pathophysiology centers on disrupted transcriptional regulation during neurodevelopment due to impaired Mediator complex function.

Molecular Pathways

Mediator Complex and RNA Polymerase II Transcription:

The Mediator complex is "a multi-protein complex that is required for Polymerase II transcription initiation" and "required for expression of most, if not all, pol II transcripts" (blok2018denovomutations pages 1-2, harper2018thecomplexstructure pages 1-2). The human Mediator contains 26 subunits organized into head, middle, and tail modules, with the reversibly associating CDK8-kinase module (consisting of MED13, MED12, CDK8, and cyclin C) (harper2018thecomplexstructure pages 1-2, poss2013themediatorcomplex pages 2-3).

As described by Poss et al. (2013), "the CDK8-module can reversibly bind Mediator...Binding of the CDK8-module to the Mediator core complex has been reported to prevent the association of the Mediator with the Pol II preinitiation complex, thus preventing transcription initiation and/or re-initiation" (poss2013themediatorcomplex pages 2-3). MED13 specifically "serves as the molecular bridge between the core Mediator complex and the kinase submodule" (blok2018denovomutations pages 7-11).

MED13-Dependent Transcriptional Regulation:

MED13 regulates transcription through multiple mechanisms: 1. Kinase Module Association: MED13 facilitates reversible binding of the CDK8-module to core Mediator, modulating transcriptional activation versus repression (blok2018denovomutations pages 1-2, poss2013themediatorcomplex pages 2-3) 2. Protein Turnover Regulation: The N-terminal phosphodegron of MED13 regulates its degradation via SCF-Fbw7, controlling CDK8-module availability. "Protein turnover of MED13 (or MED13L) may be critical in modulating the pools of Mediator-CDK8 kinase complex in cells" (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11) 3. Transcription Factor Phosphorylation: The CDK8 kinase can phosphorylate transcription factors and chromatin regulators, with MED13 helping to coordinate these activities (poss2013themediatorcomplex pages 2-3)

Cellular Processes

Neuronal Development and Migration:

Mouse studies using in utero electroporation demonstrate that "silencing Med13 in cortical neurons impaired its radial migration and contralateral projection as well as dendritic complexity" (li2026med13isinvolved pages 1-2). The authors found that "Med13 regulates cortical neuronal radial migration and callosal projection at least in part through PlxnA4," a downstream target involved in axon guidance (li2026med13isinvolved pages 1-2).

Zygotic Genome Activation:

MED13 plays a critical role in early embryonic transcriptional activation. Miao et al. (2018) demonstrated that "MED13 is essential for ZGA [zygotic genome activation] in the mouse, in part by regulating expression of the embryo-specific chromatin remodeling complex, esBAF" (miao2018mediatorcomplexcomponent pages 1-2). Knockout of Med13 in mouse embryos resulted in embryonic lethality as early as E8.5 (li2026med13isinvolved pages 1-2, miao2018mediatorcomplexcomponent pages 1-2).

Cortical Neurogenesis:

Recent work by Li et al. (2025) on MED13L (the paralog) provides insights relevant to MED13 function. They found that MED13L "orchestrates cortical neurogenesis by priming the transcriptional activation of key developmental genes, including Neurod2, Sox5, Auts2, and Nfib" through binding to the core mediator complex and facilitating "the complex's association with RNA Pol II" (blok2018denovomutations pages 1-2). Given the structural and functional similarities between MED13 and MED13L, analogous mechanisms likely apply to MED13 in neuronal differentiation.

Protein Dysfunction

Haploinsufficiency (Truncating Variants):

Truncating MED13 variants result in reduced functional protein. Western blot analysis of a nonsense variant showed that while transcript was present, "no truncated MED13 protein product could be detected" (blok2018denovomutations pages 7-11), indicating protein instability or degradation.

Altered Protein Stability and Turnover (Phosphodegron Variants):

Missense variants affecting Thr326/Pro327 prevent normal SCF-Fbw7-mediated ubiquitination and degradation, potentially leading to abnormal accumulation of MED13 protein. This could disrupt the normal dynamic regulation of Mediator-CDK8 module association (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

Altered Protein-Protein Interactions (C-terminal Variants):

C-terminal missense variants are predicted to alter surface-exposed interaction motifs, potentially disrupting MED13's interactions with other Mediator subunits or transcription factors (blok2018denovomutations pages 7-11).

Metabolic Changes

While not a primary metabolic disorder, MED13 does regulate metabolic gene expression. Studies in cardiac-specific MED13 overexpressing mice showed that "cardiac expression of MED13 decreases metabolic gene expression in the heart but enhances them in WAT [white adipose tissue]" and affects systemic energy homeostasis (baskin2014med13‐dependentsignalingfrom pages 1-2). Whether metabolic dysregulation contributes to MED13 Syndrome phenotypes remains unclear.

Immune System Involvement

No primary immune dysfunction has been reported. One patient had isolated IgA deficiency (nardi2021couldthemed13 pages 1-2), but this is not a consistent feature.

Tissue Damage Mechanisms

Neurodevelopmental Disruption:

The primary tissue damage mechanism is impaired neurodevelopment rather than progressive neurodegeneration. Brain MRI findings in severe cases show structural malformations (corpus callosum hypoplasia, optic nerve/chiasm atrophy, ventriculomegaly) (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5), indicating developmental abnormalities rather than acquired injury.

Biochemical Abnormalities

Transcriptional Dysregulation:

The core biochemical abnormality is widespread transcriptional dysregulation due to impaired Mediator function. Differential protein analysis of MED13-deficient human neuroblastoma cells "revealed a large number of dysregulated proteins" involved in neurodevelopmental pathways (li2026med13isinvolved pages 1-2).

Molecular Profiling (Where Available)

Transcriptomics:
Single-cell transcriptomics and immunofluorescence of Med13l knockout mouse embryos "reveal severe cortical neurogenesis deficits...driven by impaired neural progenitor differentiation" (blok2018denovomutations pages 1-2). Integrative multi-omics analyses revealed dysregulation of developmental genes including Neurod2, Sox5, Auts2, and Nfib (blok2018denovomutations pages 1-2).

Proteomics:
Differential protein analysis of MED13-deleted SH-SY5Y cells identified dysregulated proteins including PLXNA4, convergent towards neurodevelopmental pathways (li2026med13isinvolved pages 1-2).

Advanced Technologies

Single-Cell Analysis:
Med13l studies used single-cell RNA-seq to identify cell-type-specific deficits in cortical neurogenesis (blok2018denovomutations pages 1-2).

Functional Genomics:
CRISPR-based knockdown and overexpression studies in mouse cortical neurons demonstrated Med13's roles in migration, dendritic development, and callosal projections (li2026med13isinvolved pages 1-2).

Suggested Ontology Terms

• GO Biological Process:
• GO:0006357 (regulation of transcription by RNA polymerase II)
• GO:0045944 (positive regulation of transcription by RNA polymerase II)
• GO:0021987 (cerebral cortex development)
• GO:0021772 (olfactory bulb development)
• GO:0022008 (neurogenesis)

• GO:0051301 (cell division)

• GO Cellular Component:

• GO:0016592 (mediator complex)

• GO:0005634 (nucleus)

• Cell Types (Cell Ontology):

• CL:0000540 (neuron)
• CL:0000598 (pyramidal neuron)
• CL:0000127 (astrocyte)
• CL:0011005 (GABAergic neuron)
• CL:0000125 (glial cell)

7. Anatomical Structures Affected

Organ Level

Primary Organs: - Central Nervous System (Brain): The brain is the primary organ affected, with widespread impact on cortical development, corpus callosum formation, and optic nerve structures (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, fazio2025geneticclinicaland pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5)

Secondary Organs: - Heart: Mild to moderate congenital heart defects in 15-30% of cases (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7) - Eyes: Optic nerves, retina affected in majority of patients (62%) (blok2018denovomutations pages 6-7) - Gastrointestinal system: Chronic constipation, rare megacolon (blok2018denovomutations pages 6-7, yang2025anovelframeshift pages 2-3)

Body Systems: - Nervous system (primary) - Cardiovascular system (secondary) - Visual system (secondary) - Musculoskeletal system (hypotonia, minor skeletal anomalies)

Tissue and Cell Level

Specific Tissue Types: - Nervous tissue (cerebral cortex, corpus callosum, optic nerves, brainstem) - Cardiac muscle and connective tissue (in congenital heart defects) - Neural epithelium (retina, optic nerve)

Specific Cell Populations: - Cortical excitatory neurons (pyramidal neurons of layers II/III and V/VI) (blok2018denovomutations pages 1-2, li2026med13isinvolved pages 1-2) - Neural progenitor cells during neurogenesis (blok2018denovomutations pages 1-2, li2026med13isinvolved pages 1-2) - Retinal ganglion cells and optic nerve fibers

Subcellular Level

MED13 localizes to the nucleus as part of the Mediator complex (harper2018thecomplexstructure pages 1-2, poss2013themediatorcomplex pages 2-3).

GO Cellular Component Terms: - GO:0016592 (mediator complex) - GO:0005634 (nucleus) - GO:0000790 (nuclear chromatin)

Localization

Specific Anatomical Sites (UBERON Terms): - UBERON:0000955 (brain) - UBERON:0001869 (cerebral cortex) - UBERON:0002335 (corpus callosum) - UBERON:0000941 (cranial nerve II) - UBERON:0001873 (caudate nucleus) - UBERON:0002298 (brainstem) - UBERON:0002543 (retina) - UBERON:0000948 (heart)

Lateralization: Generally bilateral for brain and eye findings; heart defects are typically midline structures.

8. Temporal Development

Onset

Typical Age of Onset:
Congenital/prenatal for structural malformations (heart defects, dysmorphic features, brain malformations). Developmental delays apparent in infancy (first 6-12 months), with global developmental delay and motor delays recognized early. Speech delays become evident in toddler years (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5).

Onset Pattern:
- Acute: Not applicable - Chronic/Insidious: The neurodevelopmental delays emerge insidiously as milestones are missed - Congenital: Structural anomalies present from birth

Progression

Disease Stages:
No formal staging system exists. The disorder does not progress through distinct stages but rather represents a static or slowly improving developmental trajectory once established.

Progression Rate: - Developmental Trajectory: After initial recognition of delays, the developmental trajectory tends to be stable with slow progress. Speech and motor skills may improve somewhat with intensive therapy, but intellectual disability persists. - Non-Progressive: Unlike neurodegenerative disorders, MED13 Syndrome does not typically show progressive worsening. However, one patient showed "regression at the age of 13 months" in speech development (blok2018denovomutations pages 4-5), which is atypical.

Disease Course Pattern: - Stable: Generally stable neurodevelopmental disability once established - Chronic Lifelong: Lifelong condition requiring ongoing support

Disease Duration:
Lifelong condition.

Patterns

Remission:
Not applicable; this is not a relapsing-remitting condition.

Critical Periods:
Prenatal and early postnatal brain development represent critical vulnerable periods when MED13 function is essential for proper cortical neurogenesis, neuronal migration, and connectivity establishment (li2026med13isinvolved pages 1-2, miao2018mediatorcomplexcomponent pages 1-2).

9. Inheritance and Population

Epidemiology

Prevalence:
Extremely rare. As of 2025, only approximately 26-30 cases have been reported worldwide (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). True population prevalence unknown but estimated to be less than 1 per million.

Incidence:
Unknown; extremely rare. The rate of approximately 1 de novo MED13 variant per 2,200 DD/ID-affected individuals suggests it accounts for a very small fraction of neurodevelopmental disorders (blok2018denovomutations pages 7-11).

For Genetic Etiology

Inheritance Pattern:
Autosomal dominant. As Blok et al. state, "Eleven variants were confirmed to be de novo, and one patient (patient B) inherited the variant from her mother who is also affected" (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5). More recent reports include additional familial cases with mother-to-child transmission (yang2025anovelframeshift pages 2-3).

Penetrance:
Appears to be complete for core neurodevelopmental features (DD/ID, speech delay) based on all reported cases showing these features. However, variable expressivity is evident, with the same variant (p.Pro327Ser) causing different phenotypic severity in unrelated individuals (nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 4-5).

Expressivity:
Highly variable. Even individuals with the same variant show phenotypic variability. For example, the recurrent p.Pro327Ser variant was associated with both a Kabuki-like presentation and a less dysmorphic presentation with cardiac features in different patients (nardi2021couldthemed13 pages 1-2, blok2018denovomutations pages 4-5).

Genetic Anticipation:
Not reported or applicable.

Germline Mosaicism:
While not specifically documented for MED13, germline mosaicism is theoretically possible and has been reported for the related MED13L gene (fazio2025geneticclinicaland pages 1-2). Recurrence risk counseling should consider this possibility.

Founder Effects:
No founder effects or population-specific mutations have been identified. The disorder appears to arise from independent de novo mutational events across diverse populations.

Consanguinity:
Not relevant; autosomal dominant disorder arising de novo.

Carrier Frequency:
Not applicable in traditional sense; nearly all cases are de novo. However, affected individuals are heterozygous carriers who can transmit the variant to offspring with 50% probability.

Population Demographics

Affected Populations:
No specific ethnic or demographic groups show higher prevalence. Cases have been reported from diverse populations including European, North American, Asian (Chinese family), and others (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3).

Geographic Distribution:
Worldwide distribution with no geographic clustering. Cases reported from United States, Europe (Netherlands, Germany, France, Italy, UK), China, and other regions (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3).

Sex Ratio:
No strong sex bias. The original cohort included both males and females; approximately balanced sex distribution across reported cases (blok2018denovomutations pages 1-2).

Age Distribution:
Given recent disease description (2018), most reported individuals are children and young adults. One neonatal death demonstrates the potential for severe early presentations (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5).

10. Diagnostics

Clinical Tests

Laboratory Tests: - Standard metabolic panels: Generally normal; not diagnostically informative - Chromosomal microarray: Typically normal unless large deletion encompassing MED13 - Specific biochemical markers: None identified

Biomarkers: No specific circulating biomarkers have been identified for MED13 Syndrome.

Imaging Studies: - Brain MRI: May show corpus callosum abnormalities (hypoplasia, agenesis), ventriculomegaly, cerebral/cerebellar atrophy, optic nerve/chiasm abnormalities, brainstem changes in severe cases (tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, fazio2025geneticclinicaland pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5). However, many patients have normal or only mildly abnormal MRI findings. - Echocardiography: To assess for congenital heart defects - Ophthalmologic Examination: Fundoscopy, optical coherence tomography (OCT) for optic nerve assessment

Functional Tests: - Developmental assessments (Gesell Developmental Diagnostic Scale, Bayley Scales) - IQ testing (WISC, Stanford-Binet) - Speech/language evaluations - Vision and hearing assessments - Electroencephalography (EEG) if seizures suspected

Genetic Testing

Overview:
Whole exome sequencing (WES) or comprehensive neurodevelopmental gene panels are the primary diagnostic approaches. As Yang et al. (2025) describe, "Whole-exome sequencing of the proband revealed a novel heterozygous frameshift variant in the MED13 gene" (yang2025anovelframeshift pages 2-3).

Recommended Approach: - First-line: WES trio sequencing (proband + both parents) to identify de novo variants and confirm inheritance pattern - Alternative: Targeted gene panels for neurodevelopmental disorders that include MED13

Whole Exome Sequencing (WES):
WES is the most effective approach, allowing identification of rare variants across all coding regions. Trio sequencing (proband + parents) is strongly recommended to confirm de novo status, which provides strong evidence for pathogenicity (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3).

Gene Panels:
Neurodevelopmental disorder panels typically include MED13 among hundreds of other genes associated with DD/ID, autism, and epilepsy (blok2018denovomutations pages 1-2).

Single Gene Testing:
Sanger sequencing of MED13 can be used for targeted confirmation of suspected variants or for family segregation studies (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3).

Variant Interpretation:
Variants are classified using ACMG/AMP guidelines. Key criteria include: - Absence from population databases (gnomAD, TOPMED) - De novo occurrence in affected individual - High conservation of affected residues - In silico prediction scores (CADD, PolyPhen-2, SIFT, MutationTaster) - Functional data when available - Clustering of variants in functional domains (blok2018denovomutations pages 1-2, tolmacheva2024expandingphenotypeof pages 1-2, blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11, yang2025anovelframeshift pages 2-3)

Functional Validation (Research Setting): - qPCR to assess MED13 transcript levels (blok2018denovomutations pages 7-11) - Western blot to assess protein levels and detect truncated products (blok2018denovomutations pages 7-11) - Modeling of variant effects on protein structure and interactions (blok2018denovomutations pages 7-11)

Clinical Criteria

Standardized Diagnostic Criteria:
No formal consensus diagnostic criteria yet established. Clinical diagnosis based on constellation of features: - Major criteria: Developmental delay/intellectual disability AND speech/language disorder - Supportive criteria: Autism, ADHD, dysmorphic facial features, eye abnormalities, heart defects, hypotonia, motor delays - Molecular confirmation: Pathogenic or likely pathogenic variant in MED13

Differential Diagnosis: MED13 Syndrome should be distinguished from: - Kabuki syndrome: Phenotypic overlap noted; MED13 variant was identified in a patient initially suspected to have Kabuki syndrome (nardi2021couldthemed13 pages 1-2) - Other Mediator complex disorders: MED13L syndrome (more severe ID, higher seizure frequency); MED12-related X-linked ID; CDK8-related syndrome (nardi2021couldthemed13 pages 1-2, fazio2025geneticclinicaland pages 1-2, poot2019mutationsinmediator pages 1-1, fazio2025geneticclinicaland pages 2-4) - 22q11.2 deletion syndrome: Similar developmental and cardiac features - Other syndromic ID conditions: Numerous syndromes present with DD/ID, speech delays, and dysmorphic features

Screening

Newborn Screening:
Not included in standard newborn screening panels.

Carrier Screening:
Not applicable; disorder arises predominantly de novo.

Prenatal Testing:
Available for families with known pathogenic variant. Includes: - Chorionic villus sampling (CVS) - Amniocentesis - Cell-free fetal DNA testing (research/specialty labs)

Cascade Screening:
Not routinely performed; family members of affected individuals with inherited variants should receive genetic counseling and may opt for testing.

11. Outcome/Prognosis

Survival and Mortality

Survival Rate:
Generally good for typical presentations. Most individuals survive to adulthood with appropriate supportive care.

Life Expectancy:
Near-normal life expectancy expected for most patients. However, one severe neonatal case resulted in death at 76 days due to multiple organ failure (tolmacheva2024expandingphenotypeof pages 1-2, tolmacheva2024expandingphenotypeof pages 2-5), indicating that rare severe presentations can be life-threatening.

Mortality Rate:
Very low in typical cases. The neonatal death case represents the severe end of the phenotypic spectrum.

Disease-Specific Mortality:
Rare; complications from severe heart defects or epilepsy could theoretically contribute to mortality in severe cases.

Morbidity and Function

Morbidity:
Significant lifelong morbidity related to intellectual disability, speech impairment, and associated features. Quality of life can be substantially impacted by: - Educational challenges and need for special education - Social interaction difficulties, especially with comorbid autism - Communication barriers due to severe speech disorders - Visual impairment in those with optic nerve abnormalities - Chronic constipation/GI issues

Disability Outcomes:
Most individuals require ongoing support and accommodations throughout life. Degree of independence varies with severity of ID; those with mild ID may achieve semi-independent living with support, while those with moderate ID typically require more substantial lifelong assistance.

Quality of Life Measures:
Not systematically reported in published case series. Expected to be reduced compared to general population, but can be improved with appropriate therapies, educational support, and behavioral interventions.

Disease Course

Complications: - Chronic constipation (31% in original cohort) (blok2018denovomutations pages 6-7) - Feeding difficulties in infancy - Behavioral problems associated with autism/ADHD - Visual impairment from optic nerve abnormalities or uncorrected refractive errors - Seizures (rare but can be severe and drug-resistant when present) (blok2018denovomutations pages 6-7) - Orthopedic complications (scoliosis, joint issues) - Cardiac complications from congenital heart defects

Recovery Potential:
No cure or full recovery possible. However, developmental trajectory can improve with: - Intensive speech and language therapy - Physical and occupational therapy for motor skills - Educational interventions tailored to cognitive level - Behavioral therapies for autism/ADHD Some patients show meaningful gains in communication and adaptive skills with comprehensive intervention, though intellectual disability persists.

Prediction

Prognostic Factors: - Severity of ID: Mild ID associated with better functional outcomes than moderate/severe ID - Presence of seizures: Drug-resistant epilepsy associated with poorer developmental outcomes - Severity of speech impairment: Those with childhood apraxia of speech have more profound communication challenges - Cardiac defects: Severe congenital heart disease can impact overall health and development - Early intervention: Access to early intensive therapies may improve developmental trajectory

Prognostic Biomarkers:
None identified. Genotype-phenotype correlations are emerging (e.g., C-terminal variants associated with Duane anomaly), but do not yet reliably predict overall severity (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

12. Treatment

Pharmacotherapy

No Disease-Specific Pharmacological Treatments:
There are currently no medications that target the underlying genetic or molecular cause of MED13 Syndrome.

Symptomatic Pharmacotherapy: - Anti-epileptic drugs (AEDs): For patients with seizures; choice of AED depends on seizure type (e.g., valproic acid, levetiracetam for generalized seizures) - ADHD medications: Stimulants (methylphenidate, amphetamines) or non-stimulants (atomoxetine, guanfacine) for attention and behavioral management in those with ADHD - Antipsychotics/mood stabilizers: May be used for severe behavioral problems, though with caution given side effect profiles - Gastrointestinal medications: Laxatives, stool softeners, or motility agents for chronic constipation

Pharmacogenomics:
Not specifically studied for MED13 Syndrome. Standard pharmacogenomic considerations for AED metabolism and ADHD medication response may apply.

Advanced Therapeutics

Gene Therapy:
Not currently available. Given the autosomal dominant inheritance with likely gain-of-dysfunction mechanisms for some variants (phosphodegron mutations), gene therapy would be complex, potentially requiring allele-specific silencing or gene editing rather than simple gene addition.

Cell Therapy:
Not applicable.

RNA-Based Therapies:
Not currently available. Antisense oligonucleotides (ASOs) targeting mutant MED13 transcripts could theoretically be developed for specific variants.

Targeted Therapies:
None currently available.

Surgical and Interventional

Cardiac Surgery:
Surgical correction or intervention for congenital heart defects as indicated (e.g., repair of ventricular septal defects, coarctation repair) (tolmacheva2024expandingphenotypeof pages 1-2).

Gastrointestinal Surgery:
Surgical management for severe constipation or megacolon if conservative management fails (yang2025anovelframeshift pages 2-3).

Orthopedic Interventions:
Management of scoliosis, hip dysplasia, or other skeletal abnormalities as needed.

Supportive and Rehabilitative

Speech and Language Therapy:
Essential intervention for all patients given universal speech/language impairment. Focus on: - Augmentative and alternative communication (AAC) for those with severe apraxia - Oral motor therapy - Language comprehension and expression training

Physical Therapy:
For motor delays and hypotonia; aims to improve gross motor skills, strength, coordination.

Occupational Therapy:
To develop fine motor skills, adaptive behaviors, and activities of daily living.

Educational Interventions:
Individualized Education Programs (IEPs) tailored to cognitive abilities; may include special education services, classroom accommodations, one-on-one aides.

Behavioral Therapies:
- Applied Behavior Analysis (ABA) for autism-related behaviors - Cognitive-behavioral therapy (CBT) for older children/adults with ADHD or anxiety - Social skills training

Ophthalmologic Care:
Regular eye exams; correction of refractive errors; low vision services if visual impairment present; monitoring for progressive optic atrophy.

Cardiac Monitoring:
Regular cardiology follow-up for those with congenital heart defects.

Nutritional Support:
Management of feeding difficulties in infancy; dietary modifications for constipation.

Experimental

Clinical Trials:
No specific clinical trials for MED13 Syndrome are currently registered. Patients may be eligible for trials targeting broader categories (neurodevelopmental disorders, intellectual disability).

Treatment Outcomes

Treatment Response:
Supportive therapies can improve functional outcomes and quality of life, but do not reverse the underlying disorder. Speech therapy can lead to meaningful communication gains in some patients. Behavioral therapies can reduce problematic behaviors and improve social functioning.

Side Effects:
Depend on specific medications used. AEDs may cause sedation, cognitive effects. ADHD medications may cause appetite suppression, sleep disturbances. Surgical interventions carry standard operative risks.

Treatment Strategy

Multidisciplinary Approach:
Optimal management involves coordinated care from: - Medical geneticist - Developmental pediatrician or neurologist - Speech-language pathologist - Physical and occupational therapists - Educational specialists - Behavioral therapist/psychologist - Ophthalmologist - Cardiologist (if heart defects present) - Gastroenterologist (if GI issues present)

Treatment Algorithms:
No formal published algorithms. General approach: 1. Confirm genetic diagnosis via WES 2. Comprehensive baseline assessments (developmental, speech/language, cardiac, ophthalmologic) 3. Initiate early intervention therapies (speech, PT, OT) 4. Enroll in appropriate educational programs with IEP 5. Manage comorbidities (seizures, ADHD, GI issues) as they arise 6. Provide genetic counseling to family 7. Ongoing monitoring and adjustment of therapies

Suggested MAXO Terms: - MAXO:0000011 (speech therapy) - MAXO:0000127 (physical therapy) - MAXO:0000128 (occupational therapy) - MAXO:0000218 (special education) - MAXO:0000058 (pharmaceutical therapy) - for symptomatic medications - MAXO:0001298 (genetic counseling)

13. Prevention

Prevention Levels

Primary Prevention:
Not applicable for de novo genetic disorder. However, preconception genetic counseling for rare families with inherited variants can inform reproductive decisions.

Secondary Prevention:
Early diagnosis through comprehensive developmental screening and genetic testing allows for: - Early intervention therapies to optimize developmental outcomes - Appropriate medical surveillance (cardiac, ophthalmologic) - Family planning and genetic counseling for future pregnancies

Tertiary Prevention:
Ongoing management to prevent complications: - Regular ophthalmology to detect and treat progressive vision problems - Cardiac monitoring to prevent decompensation of heart defects - Aggressive management of constipation to prevent bowel obstruction - Seizure management to prevent status epilepticus

Screening and Early Detection

Newborn Screening:
Not currently included.

Genetic Screening: - Prenatal Testing: Available for families with known MED13 variant; chorionic villus sampling or amniocentesis - Preimplantation Genetic Diagnosis (PGD): Theoretically available for families with known variant who undergo IVF - Carrier Screening: Not applicable; disorder arises de novo in vast majority of cases

Risk Stratification:
Families with one affected child have recurrence risk primarily dependent on possibility of parental germline mosaicism (estimated 1-2% based on other dominant disorders), unless a parent is confirmed to carry the variant (50% recurrence risk per pregnancy).

Counseling

Genetic Counseling:
Essential component of care. Should cover: - Explanation of autosomal dominant inheritance - De novo occurrence in vast majority of cases - Low recurrence risk for parents of affected child (unless parent is carrier) - 50% transmission risk for affected individuals if they reproduce - Availability of prenatal testing/PGD for future pregnancies - Natural history and expected outcomes - Support resources and family organizations

As stated by Yang et al. (2025), "This study also highlights the importance of preconception genetic counseling for couples with suspected genetic disease" (yang2025anovelframeshift pages 2-3).

14. Other Species / Natural Disease

Taxonomy

MED13 orthologs exist across eukaryotes, reflecting its ancient and essential role in transcriptional regulation (poss2013themediatorcomplex pages 2-3).

• Humans (Homo sapiens): NCBI Taxon 9606
• Mouse (Mus musculus): NCBI Taxon 10090
• Zebrafish (Danio rerio): NCBI Taxon 7955
• Fruit fly (Drosophila melanogaster): NCBI Taxon 7227
• Nematode (Caenorhabditis elegans): NCBI Taxon 6239
• Yeast (Saccharomyces cerevisiae): NCBI Taxon 4932

Gene Orthologs

Human MED13 has orthologs across species with varying degrees of sequence conservation. According to Poss et al. (2013), MED13 shows 13% identity to yeast Saccharomyces cerevisiae, 27% to Drosophila, and 94% to mouse (poss2013themediatorcomplex pages 2-3).

Natural Disease

No naturally occurring MED13-related neurodevelopmental disorders have been documented in veterinary medicine or wildlife populations. This is likely due to: 1. Embryonic lethality of complete loss-of-function 2. Reduced reproductive fitness of affected individuals 3. Limited veterinary genetic diagnostics for rare neurodevelopmental conditions

Comparative Biology

Evolutionary Conservation:
MED13 function is highly conserved. As noted by Poss et al., "MED13, as well as the other subunits of the CDK8-module, are known to be critical regulators of developmental gene expression programs in Drosophila, zebrafish and C. elegans" (blok2018denovomutations pages 7-11).

15. Model Organisms

Model Types and Systems

Mammalian Models:

Mouse (Mus musculus):

Complete Knockout:
Complete Med13 knockout in mice results in embryonic lethality. As reported by Miao et al. (2018), "genetic inactivation of Med13 caused embryonic lethality as early as embryonic day (E) 8.5 in mouse" (miao2018mediatorcomplexcomponent pages 1-2), indicating absolute requirement for early development.

Conditional Knockout Models:
Conditional Med13 knockout models have been generated to study tissue-specific functions: - Cardiac-specific knockout: Med13 floxed allele with cardiac-specific Cre demonstrated roles in cardiac metabolism and systemic energy homeostasis (baskin2014med13‐dependentsignalingfrom pages 1-2) - Skeletal muscle-specific knockout: Demonstrated Med13 roles in glucose homeostasis (baskin2014med13‐dependentsignalingfrom pages 1-2) - Oocyte-specific knockout: Showed Med13 is essential for zygotic genome activation (miao2018mediatorcomplexcomponent pages 1-2)

In Utero Electroporation Models:
Li et al. (2026) used in utero electroporation to knock down Med13 in developing cortical neurons, demonstrating that "silencing Med13 in cortical neurons impaired its radial migration and contralateral projection as well as dendritic complexity in mice" (li2026med13isinvolved pages 1-2). This model recapitulates neurodevelopmental aspects of the human syndrome.

Heterozygous Models:
While full characterization of heterozygous Med13 mice phenotype is not extensively published, such models would be most relevant to human haploinsufficiency. Studies suggest heterozygous mice may display some neurodevelopmental phenotypes (li2026med13isinvolved pages 1-2).

Invertebrate Models:

Drosophila melanogaster:
Studies in Drosophila have shown that Med12 and Med13 subunits are "essential for the transcription of Wingless target genes" and play critical developmental roles (poss2013themediatorcomplex pages 2-3). Drosophila models provide insights into conserved Mediator functions in development.

Caenorhabditis elegans:
C. elegans has been used to study Mediator complex functions in development, though specific Med13 models for neurodevelopmental phenotypes are not extensively characterized in the context of human disease modeling.

Cellular Models

Human Neuroblastoma Cells (SH-SY5Y):
Li et al. (2026) generated MED13-deficient SH-SY5Y cells using CRISPR-Cas9. "Differential protein analysis of human MED13-deficient SH-SY5Y cells revealed a large number of dysregulated proteins, including PLXNA4" (li2026med13isinvolved pages 1-2), providing insights into downstream pathways affected by MED13 loss.

Induced Pluripotent Stem Cells (iPSCs):
While not yet reported for MED13 patients specifically, iPSC-derived neurons from patients would be valuable for studying disease mechanisms and testing therapeutics.

Primary Fibroblasts:
Western blot studies on patient blood mononuclear cells have been used to assess MED13 protein levels (blok2018denovomutations pages 7-11). Patient fibroblasts could similarly be used for biochemical studies.

Model Characteristics

Phenotype Recapitulation:

Mouse Models: - Embryonic lethality in complete knockouts recapitulates the essential developmental role - Neuronal migration and dendritic defects in conditional/knockdown models parallel human neurodevelopmental abnormalities - Metabolic phenotypes in tissue-specific models may relate to systemic features in some patients

Limitations:
- Complete knockout mice die early in embryogenesis, precluding study of postnatal neurodevelopmental trajectory - Heterozygous mice have not been fully characterized for all features of human syndrome - Mouse models cannot fully recapitulate human-specific higher cognitive functions and speech

Applications:

Research Applications: - Understanding transcriptional mechanisms during neurogenesis and neuronal migration - Identifying downstream targets and pathways (e.g., PlxnA4 in migration) (li2026med13isinvolved pages 1-2) - Testing potential therapeutic interventions in preclinical setting - Studying genotype-phenotype correlations by introducing specific patient variants

Resources

Model Organism Databases: - MGI (Mouse Genome Informatics): Med13 gene ID MGI:1916232 - RGD (Rat Genome Database): Med13 ortholog information - FlyBase: Drosophila Med13 ortholog - WormBase: C. elegans Med13 ortholog - IMSR (International Mouse Strain Resource): For locating specific Med13 mouse models - KOMP (Knockout Mouse Project): Resources for generating knockout models

Summary Tables

For ease of reference, two comprehensive tables summarizing clinical phenotypes and genetic/molecular features are provided below.

Table: This table summarizes the core and variable clinical features reported for MED13 syndrome, including approximate frequencies, severity patterns, onset, suggested HPO mappings, and supporting citations. It is useful for disease knowledge base curation and phenotype annotation.

Table: This table summarizes the reported genetic and molecular features of MED13 syndrome, including representative variants, domains, clustering, functional interpretations, and available in silico evidence. It is useful for disease knowledge base curation and for distinguishing truncating versus hotspot missense mechanisms.

Conclusions

MED13 Syndrome represents a recently recognized autosomal dominant neurodevelopmental disorder characterized by universal developmental delay/intellectual disability and speech/language disorders, along with variable additional features including autism, ADHD, dysmorphic facial features, ophthalmologic abnormalities, and mild cardiac defects (blok2018denovomutations pages 1-2, blok2018denovomutations pages 4-5, fazio2025geneticclinicaland pages 1-2). The disorder results from heterozygous pathogenic variants in the MED13 gene, which encodes a critical subunit of the CDK8-kinase module of the Mediator complex essential for RNA polymerase II transcription (blok2018denovomutations pages 1-2, harper2018thecomplexstructure pages 1-2).

With only 26-30 cases reported worldwide as of 2025, MED13 Syndrome is extremely rare (yang2025anovelframeshift pages 1-2, yang2025anovelframeshift pages 2-3). The vast majority of cases arise from de novo variants, though rare familial transmission with variable expressivity has been documented (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3). The pathogenic mechanism likely involves both haploinsufficiency (for truncating variants) and gain-of-dysfunction (for specific missense variants affecting protein stability and interactions) (blok2018denovomutations pages 6-7, blok2018denovomutations pages 7-11).

Currently, no disease-modifying treatments exist, and management is entirely supportive, focusing on intensive speech/language therapy, educational interventions, behavioral therapies, and management of associated medical issues (blok2018denovomutations pages 1-2). Prognosis is generally favorable for survival, though lifelong disability and need for support are expected. Further research using animal models and patient-derived cells is elucidating the molecular mechanisms and may inform future therapeutic development (li2026med13isinvolved pages 1-2, miao2018mediatorcomplexcomponent pages 1-2).

Early genetic diagnosis through whole exome sequencing is crucial for enabling early intervention, appropriate medical surveillance, accurate prognostic counseling, and informed family planning (blok2018denovomutations pages 1-2, yang2025anovelframeshift pages 2-3). As additional cases are identified and reported, genotype-phenotype correlations will be refined, and the full clinical spectrum will be better delineated.

References

All citations refer to context IDs from the gathered evidence: - pqac-00000001: Blok et al. 2018 - Foundational cohort study - pqac-00000002, pqac-00000016: Tolmacheva et al. 2024 - Severe neonatal case - pqac-00000003: Rivera et al. 2024 - ASD case report - pqac-00000004, pqac-00000017: Yang et al. 2025 - Chinese family - pqac-00000005: Nardi et al. 2021 - Kabuki-like case - pqac-00000006, pqac-00000007, pqac-00000008, pqac-00000015: Blok et al. 2018 detailed phenotype/variant data - pqac-00000009, pqac-00000019: Fazio et al. 2025 - MEDopathies review - pqac-00000010: Li et al. 2026 - Mouse neurodevelopmental studies - pqac-00000011: Baskin et al. 2014 - Med13 metabolic functions - pqac-00000012: Harper & Taatjes 2018 - Mediator structure - pqac-00000013: Poss et al. 2013 - Mediator complex review - pqac-00000014: Miao et al. 2018 - Med13 in ZGA - pqac-00000018: Poot 2019 - Mediator complex disorders

Publication dates range from 2013-2026, with emphasis on recent 2023-2025 sources as requested.

References

1. (blok2018denovomutations pages 1-2): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

2. (yang2025anovelframeshift pages 1-2): Qi Yang, Qiang Zhang, Sheng Yi, Gaojie Huang, Xunzhao Zhou, Shang Yi, and Jingsi Luo. A novel frameshift variant in the med13 gene causing intellectual developmental disorder-61 in a chinese family. Frontiers in Pediatrics, Oct 2025. URL: https://doi.org/10.3389/fped.2025.1699544, doi:10.3389/fped.2025.1699544. This article has 1 citations.

3. (yang2025anovelframeshift pages 2-3): Qi Yang, Qiang Zhang, Sheng Yi, Gaojie Huang, Xunzhao Zhou, Shang Yi, and Jingsi Luo. A novel frameshift variant in the med13 gene causing intellectual developmental disorder-61 in a chinese family. Frontiers in Pediatrics, Oct 2025. URL: https://doi.org/10.3389/fped.2025.1699544, doi:10.3389/fped.2025.1699544. This article has 1 citations.

4. (blok2018denovomutations pages 4-5): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

5. (harper2018thecomplexstructure pages 1-2): Thomas M. Harper and Dylan J. Taatjes. The complex structure and function of mediator. Journal of Biological Chemistry, 293:13778-13785, Sep 2018. URL: https://doi.org/10.1074/jbc.r117.794438, doi:10.1074/jbc.r117.794438. This article has 120 citations and is from a domain leading peer-reviewed journal.

6. (tolmacheva2024expandingphenotypeof pages 1-2): Ekaterina Tolmacheva, Anna S. Bolshakova, Jekaterina Shubina, Margarita S. Rogacheva, Alexey N. Ekimov, Julia L. Podurovskaya, Artem A. Burov, Denis V. Rebrikov, Vladimir G. Bychenko, Dmitry Yu. Trofimov, and Gennady T. Sukhikh. Expanding phenotype of med13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies. BMC Medical Genomics, May 2024. URL: https://doi.org/10.1186/s12920-024-01857-z, doi:10.1186/s12920-024-01857-z. This article has 8 citations and is from a peer-reviewed journal.

7. (rivera2024med13genemutation pages 1-2): Marlene D Rivera, Stephanie N Aponte, Felix Rivera, Norma J Arciniegas, and Simón Carlo. Med13 gene mutation related to autism spectrum disorder: a case report. Cureus, May 2024. URL: https://doi.org/10.7759/cureus.59904, doi:10.7759/cureus.59904. This article has 5 citations.

8. (nardi2021couldthemed13 pages 1-2): Laura De Nardi, Flavio Faletra, Adamo Pio D'Adamo, Anna Monica Rosaria Bianco, Emmanouil Athanasakis, Irene Bruno, and Egidio Barbi. Could the med13 mutations manifest as a kabuki‐like syndrome? American Journal of Medical Genetics Part A, 185:584-590, Nov 2021. URL: https://doi.org/10.1002/ajmg.a.61994, doi:10.1002/ajmg.a.61994. This article has 11 citations.

9. (fazio2025geneticclinicaland pages 1-2): Alessandro Fazio, Roberta Leonardi, Lorenzo Aliotta, Manuela Lo Bianco, Gennaro Anastasio, Giuseppe Messina, Corrado Spatola, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Martino Ruggieri, and Emanuele David. Genetic, clinical and neuroradiological spectrum of med-related disorders: an updated review. Genes, 16:1444, Dec 2025. URL: https://doi.org/10.3390/genes16121444, doi:10.3390/genes16121444. This article has 1 citations.

10. (fazio2025geneticclinicaland pages 2-4): Alessandro Fazio, Roberta Leonardi, Lorenzo Aliotta, Manuela Lo Bianco, Gennaro Anastasio, Giuseppe Messina, Corrado Spatola, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Martino Ruggieri, and Emanuele David. Genetic, clinical and neuroradiological spectrum of med-related disorders: an updated review. Genes, 16:1444, Dec 2025. URL: https://doi.org/10.3390/genes16121444, doi:10.3390/genes16121444. This article has 1 citations.

11. (poss2013themediatorcomplex pages 2-3): Zachary C. Poss, Christopher C. Ebmeier, and Dylan J. Taatjes. The mediator complex and transcription regulation. Critical Reviews in Biochemistry and Molecular Biology, 48:575-608, Oct 2013. URL: https://doi.org/10.3109/10409238.2013.840259, doi:10.3109/10409238.2013.840259. This article has 481 citations and is from a peer-reviewed journal.

12. (blok2018denovomutations pages 6-7): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

13. (blok2018denovomutations pages 7-11): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

14. (miao2018mediatorcomplexcomponent pages 1-2): Yi-Liang Miao, Andrés Gambini, Yingpei Zhang, Elizabeth Padilla-Banks, Wendy N Jefferson, Miranda L Bernhardt, Weichun Huang, Leping Li, and Carmen J Williams. Mediator complex component med13 regulates zygotic genome activation and is required for postimplantation development in the mouse†, ‡. Biology of Reproduction, 98:449-464, Apr 2018. URL: https://doi.org/10.1093/biolre/ioy004, doi:10.1093/biolre/ioy004. This article has 51 citations and is from a peer-reviewed journal.

15. (blok2018denovomutations pages 2-4): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

16. (blok2018denovomutations pages 5-6): Lot Snijders Blok, Susan M. Hiatt, Kevin M. Bowling, Jeremy W. Prokop, Krysta L. Engel, J. Nicholas Cochran, E. Martina Bebin, Emilia K. Bijlsma, Claudia A. L. Ruivenkamp, Paulien Terhal, Marleen E. H. Simon, Rosemarie Smith, Jane A. Hurst, Heather McLaughlin, Richard Person, Amy Crunk, Michael F. Wangler, Haley Streff, Joseph D. Symonds, Sameer M. Zuberi, Katherine S. Elliott, Victoria R. Sanders, Abigail Masunga, Robert J. Hopkin, Holly A. Dubbs, Xilma R. Ortiz-Gonzalez, Rolph Pfundt, Han G. Brunner, Simon E. Fisher, Tjitske Kleefstra, and Gregory M. Cooper. De novo mutations in med13, a component of the mediator complex, are associated with a novel neurodevelopmental disorder. Human Genetics, 137:375-388, May 2018. URL: https://doi.org/10.1007/s00439-018-1887-y, doi:10.1007/s00439-018-1887-y. This article has 95 citations and is from a peer-reviewed journal.

17. (tolmacheva2024expandingphenotypeof pages 2-5): Ekaterina Tolmacheva, Anna S. Bolshakova, Jekaterina Shubina, Margarita S. Rogacheva, Alexey N. Ekimov, Julia L. Podurovskaya, Artem A. Burov, Denis V. Rebrikov, Vladimir G. Bychenko, Dmitry Yu. Trofimov, and Gennady T. Sukhikh. Expanding phenotype of med13-associated syndrome presenting novel de novo missense variant in a patient with multiple congenital anomalies. BMC Medical Genomics, May 2024. URL: https://doi.org/10.1186/s12920-024-01857-z, doi:10.1186/s12920-024-01857-z. This article has 8 citations and is from a peer-reviewed journal.

18. (li2026med13isinvolved pages 1-2): Ze-Xuan Li, Si-Xin Tu, Yi-Wei Li, Zhi-Bin Hu, Wei-Tang Liu, Yun-Chao Tao, Li Zhao, Ning-Ning Song, Jia-Yin Chen, Qiong Zhang, Cong-Cong Qi, Hong-Wen Zhu, Yu-Qiang Ding, and Ling Hu. Med13 is involved in the radial migration and contralateral projection of cortical neurons via plxna4. Communications Biology, Feb 2026. URL: https://doi.org/10.1038/s42003-026-09704-w, doi:10.1038/s42003-026-09704-w. This article has 0 citations and is from a peer-reviewed journal.

19. (baskin2014med13‐dependentsignalingfrom pages 1-2): Kedryn K Baskin, Chad E Grueter, Christine M Kusminski, William L Holland, Angie L Bookout, Santosh Satapati, Y Megan Kong, Shawn C Burgess, Craig R Malloy, Philipp E Scherer, Christopher B Newgard, Rhonda Bassel‐Duby, and Eric N Olson. med13‐dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver. EMBO Molecular Medicine, 6:1610-1621, Nov 2014. URL: https://doi.org/10.15252/emmm.201404218, doi:10.15252/emmm.201404218. This article has 108 citations and is from a highest quality peer-reviewed journal.

20. (poot2019mutationsinmediator pages 1-1): Martin Poot. Mutations in mediator complex genes cdk8, med12, med13, and medl13 mediate overlapping developmental syndromes. Molecular Syndromology, 10:239-242, Aug 2019. URL: https://doi.org/10.1159/000502346, doi:10.1159/000502346. This article has 23 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01